Navigation Links
Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
Date:8/21/2014

St. Louis, MO (PRWEB) August 21, 2014

Gallus BioPharmaceuticals, LLC, a premier, full service biopharmaceutical contract development and manufacturing organization (CMO) announced today that it has been selected by Progenics Pharmaceuticals, Inc., an oncology company focused on the development of innovative approaches to targeting and treating cancer, to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in Progenics’ PSMA ADC product candidate. Under the agreement the antibody will be produced in Gallus’ commercial manufacturing facility in St. Louis, Missouri.

“Our extensive commercial manufacturing experience and proven quality systems make Gallus an ideal partner to support Progenics in the manufacture of their anti-PSMA antibody," said Mark R. Bamforth, President & CEO of Gallus. "We look forward to working with Progenics as they advance this treatment for patients with prostate cancer."

PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug selectively to prostate cancer cells. It does so by targeting the three-dimensional structure of PSMA, a protein that is a clinically validated biomarker of prostate cancer which is expressed on the surface of prostate cancer cells. The PSMA antibody produced at Gallus is designed to internalize into the cancer cell, release active anti-cancer drug, and destroy the malignant cell.

"Gallus has impressed us with their ability to meet our high standards, combined with the experience and expertise necessary to manufacture our anti-PSMA antibody,” said Nitya Ray, PhD, Sr. Vice President, Manufacturing of Progenics. “We look forward to a productive partnership with Gallus as we develop this product for patients in need of this therapy."

About Gallus BioPharmaceuticals

Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional development and manufacturing services to its clients. Gallus’ world-class facility in St. Louis is distinguished by nearly three decades of biologics development and over a decade of commercial cGMP manufacturing, including the ongoing manufacturing of Stelara® and Remicade® for Janssen Pharmaceuticals. Gallus’ facility in Princeton, New Jersey, has three decades of experience in process development and clinical manufacturing of bulk and aseptic-filling of mAbs, as well as large and complex proteins such as Fc-fusion proteins, IgMs and collagens, plus over 20 years of experience of commercial manufacture including the supply of ProstaScint®. Both sites maintain exemplary quality and regulatory records. For additional information, please visit http://www.gallusbiopharma.com.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics’ first-in-class PSMA targeted technology platform includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule targeted imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. For additional information, please visit http://www.progenics.com.

This press release may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other development activities; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. Information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Information on or accessed through its website is not included in its SEC filings.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12110829.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
2. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
3. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
4. Metabolix, Inc. Enters into Private Placement Agreement with Investors to Raise $25 Million in Equity Financing
5. Sequenom Enters Into License Agreement With Mayo Medical Laboratories
6. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
7. Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
8. New Technology and Healthcare Environment Present Both Challenges and Opportunities for Pharmaceutical Call Centers
9. Leading Cancer Research Centers Team Up To Launch Biotech Startup Focused On Cancer Immunotherapy
10. Convey Computer to OEM Dell Servers to Accelerate Data Intensive Applications for Data Centers
11. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... Fla. (PRWEB) , ... September 10, 2019 , ... ... to broadcast 1Q/2020 will educate about the latest developments in genome sequencing analysis. ... learn about the innovation taking place at Rivermap Research & Consulting and will ...
(Date:9/8/2019)... ... 2019 , ... The Blavatnik Family Foundation and ... and six Finalists of the 2019 Blavatnik Regional Awards for Young Scientists ... Jersey, and Connecticut since 2007, the Blavatnik Regional Awards recognize outstanding researchers in ...
(Date:9/2/2019)... LIÉGE, Belgium (PRWEB) , ... September 02, 2019 ... ... for epigenetics research and in vitro diagnostics, has launched the industry’s first epigenetics ... the underlying biological meaning of epigenetic data and other data types. , Next ...
(Date:8/29/2019)... , ... August 29, 2019 , ... ... to teach in the Sustainable Medicines in Africa program, which includes a master’s ... place in Arusha, Tanzania September 2nd through 13th, 2019. Topics to be ...
Breaking Biology Technology:
(Date:8/15/2019)... (PRWEB) , ... August 15, 2019 , ... ... patients, and relieve lab staff of routine tasks. That was the message at ... to market researcher Kalorama Information. The American Association for Clinical Chemistry (AACC) Annual ...
(Date:8/14/2019)... ... August 14, 2019 , ... Representatives with MyBioGate announced ... Exhibition Center in Boston. , “We help innovative projects connect with Chinese pharma and ... MyBioGate. , Guo went on to explain that as a part of Biotech Week ...
(Date:8/9/2019)... ... ... With a demand in healthcare to lower unneeded emergency room visits and provide ... in the coming years, according to a new report on the industry by market ... is a detailed look at the current state of these healthcare outlets, including the ...
Breaking Biology News(10 mins):